Key result
The SARS-CoV-2 neutralizing antibody STE90-C11 binds to the ACE2-RBD interface, is tolerant to most known RBD mutations, and demonstrates in vivo efficacy in hamster and hACE2 mice models.
Its licence doesn't allow us to show a copy here.
The SARS-CoV-2 neutralizing antibody STE90-C11 shows preclinical efficacy and broad tolerance to RBD mutations, supporting its clinical development for COVID-19 treatment.
STE90-C11 offers a mutation-tolerant candidate; leaves open clinical translation pending human trials.
in a plaque-based live SARS-CoV-2 neutralization assay. The in vivo efficacy of the antibody is demonstrated in the Syrian hamster and in the human angiotensin-converting enzyme 2 (hACE2) mice model. The crystal structure of STE90-C11 Fab in complex with SARS-CoV-2-RBD is solved at 2.0 Å resolution showing that the antibody binds at the same region as ACE2 to RBD. The binding and inhibition of STE90-C11 is not blocked by many known emerging RBD mutations. STE90-C11-derived human IgG1 with FcγR-silenced Fc (COR-101) is undergoing Phase Ib/II clinical trials for the treatment of moderate to severe COVID-19.
No takes yet. Share an insight, caveat, or question.
Bertoglio et al. (2021) studied COVID-19. STE90-C11 (COR-101) was evaluated. The SARS-CoV-2 neutralizing antibody STE90-C11 binds to the ACE2-RBD interface, is tolerant to most known RBD mutations, and demonstrates in vivo efficacy in hamster and hACE2 mice models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: